Post‐therapeutic acute leukemia

66Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This study reports 35 cases of posttherapeutic acute leukemia and reviews the literature on this subject. These AL's are characterized by a high incidence of anemia, in particular refractory anemia, preceding the hematological disorder by several months, by the frequent finding of myelofibrosis, by the essentially granulocytic nature of the AL, and by the low rate of remission and the, in general, extremely short survival of a few months. These leukemias may develop following continuous chemotherapy with an alkylating agent, radiotherapy of various extent, or most commonly following intensive treatment with extensive irradiation and polychemotherapy as in the management of Hodgkin's disease. In view of these therapeutic hazards, the present objectives are the modification of alkylating agent therapy by the use of other drugs and sequential administration, and a reduction in the dose and field of irradiation and the duration of polychemotherapy, as in Hodgkin's disease; all present protocols are orientated in this direction. Copyright © 1979 American Cancer Society

Cite

CITATION STYLE

APA

Auclerc, G., Jacquillat, C., Auclerc, M. F., Weil, M., & Bernard, J. (1979). Post‐therapeutic acute leukemia. Cancer, 44(6), 2017–2025. https://doi.org/10.1002/1097-0142(197912)44:6<2017::AID-CNCR2820440609>3.0.CO;2-A

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free